SEOM clinical guideline for the management of cutaneous melanoma (2020)
Author
Date
2021-05Permanent link
https://hdl.handle.net/11351/6887DOI
10.1007/s12094-020-02539-9
ISSN
1699-3055
WOS
000624437100001
PMID
33651321
Abstract
Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. The diagnosis must be histological and determination of BRAF status has to be performed in patients with stage ≥ III. Stage I–III resectable melanomas will be treated surgically. In patients with stage III melanoma, adjuvant treatment with immunotherapy or targeted therapy is also recommended. Patients with unresectable or metastatic melanoma will receive treatment with immunotherapy or targeted therapy, the optimal sequence of these treatments remains unclear. Brain metastases require a separate consideration, since, in addition to systemic treatment, they may require local treatment. Patients must be followed up closely to receive or change treatment as soon as their previous clinical condition changes, since multiple therapeutic options are available.
Keywords
Adjuvant treatment; Melanoma; StagingBibliographic citation
Majem M, Manzano JL, Marquez-Rodas I, Mujika K, Muñoz-Couselo E, Pérez-Ruiz E, et al. SEOM clinical guideline for the management of cutaneous melanoma (2020). Clin Transl Oncol. 2021 May;23:948–960.
Audience
Professionals
This item appears in following collections
- HVH - Articles científics [4476]
- VHIO - Articles científics [1250]
The following license files are associated with this item:





